Bharat Parenterals Ltd: Why Is It Outperforming Nifty 500?

Bharat Parenterals Ltd's latest quarterly results (Mar 2026) show

• PAT Growth YoY: +13.6% (stable)
• Revenue Growth YoY: -4.2%
• Operating Margin: -0.5% (volatile)

Bharat Parenterals Ltd's profit is growing with an stable trend.

• PAT Growth YoY: +13.6% (latest quarter)
• PAT Growth QoQ: +15.6% (sequential)
• 3-Year PAT CAGR: -31.3%
• Trend: Stable — consistent growth pattern

Bharat Parenterals Ltd's revenue growth trend is inflecting downward.

• Revenue Growth YoY: -4.2%
• Revenue Growth QoQ: +52.8% (sequential)
• 3-Year Revenue CAGR: +16.5%

Bharat Parenterals Ltd's operating margin is volatile.

• Current OPM: -0.5%
• OPM Change YoY: -2.7% basis points
• OPM Change QoQ: -3.2% basis points

Bharat Parenterals Ltd's long-term compounding rates

• 3-Year Profit CAGR: -31.3%
• 3-Year Revenue CAGR: +16.5%

Bharat Parenterals Ltd's earnings growth is stable with improving on a sequential basis.

• YoY Acceleration: +36.3% bps
• Sequential Acceleration: +28.0% bps
• Margin Warning: Operating margins are under pressure

Bharat Parenterals Ltd's trailing twelve month (TTM) performance

• TTM PAT: ₹-27 Cr
• TTM PAT Growth: +37.5% YoY
• TTM Revenue: ₹345 Cr
• TTM Revenue Growth: +1.5% YoY
• TTM Operating Margin: 4.6%

Bharat Parenterals Ltd appears significantly overvalued based on our fair value analysis.

• Valuation Signal: Significantly Overvalued
• Price-to-Book: 2.9x

Bharat Parenterals Ltd's price-to-book ratio is 2.9x.

• Price-to-Book (P/B): 2.9x
• Book Value per Share: ₹468
• Current Price: ₹1350

Bharat Parenterals Ltd is rated Weak with a fundamental score of 31.39/100. This score is calculated from objective financial metrics

• Revenue Growth YoY: -4.2% (10% weight)
• PAT Growth YoY: +13.6% (10% weight)
• PAT Growth QoQ: +15.6% (10% weight)
• Margins stable (10% weight)

Bharat Parenterals Ltd has a debt-to-equity ratio of N/A.

• Total Debt: ₹146 Cr

Bharat Parenterals Ltd's return ratios over recent years

• FY2024: ROCE 7.0%
• FY2025: ROCE -4.0%
• FY2026: ROCE -2.0%

Bharat Parenterals Ltd's operating cash flow is positive (FY2026).

• Cash from Operations (CFO): ₹38 Cr
• Free Cash Flow (FCF): ₹47 Cr

Bharat Parenterals Ltd's current dividend yield is 0.07%.

• Dividend Yield: 0.07%
• Current Price: ₹1350

Bharat Parenterals Ltd's shareholding pattern (Mar 2026)

• Promoters: 67.2%
• FII (Foreign): 0.1%
• DII (Domestic): 1.1%
• Public: 31.6%

Bharat Parenterals Ltd's promoter holding has decreased recently.

• Current Promoter Holding: 67.2% (Mar 2026)
• Previous Quarter: 67.2% (Dec 2025)
• Change: -0.02% (decreasing — worth monitoring)

Bharat Parenterals Ltd has been outperforming Nifty 500 for 1 consecutive week, indicating early-stage outperformance.

Bharat Parenterals Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.

Based on quantitative research signals, here is why Bharat Parenterals Ltd may be worth studying

• Earnings growing at +13.6% YoY
• Cash flow is positive — CFO ₹38 Cr

Bharat Parenterals Ltd investment thesis summary:

Bharat Parenterals Ltd's forward outlook based on current data signals

• Earnings Trend: stable
• Revenue Trend: inflecting downward
• Margin Trend: volatile
• Valuation: Significantly Overvalued